CELLINK and partners have been granted project financing from EU totaling €5,700,000 for the Giotto project. CELLINKs portion of the grant is €300,000

The project aims to develop three different medical devices designed to treat specific osteoporotic fractures through a synergistic convergence of smart nanomaterials, 3D fabrication technologies and targeted cell activation. The overall objective of GIOTTO is to implement solutions and tools to enhance active ageing thereby mitigating the economic burden to health systems and bringing within grasp benefits for the old.

CELLINK has been awarded project funding from the EU for the project “GIOTTO”- Active AgeIng and Osteoporosis: The next challenge for smart nanobiomaterials and 3D technologies through “Horizon 2020- Osteoarticular tissues regeneration.” Together with 13 partners (Politecnico di Torino, University of Pisa, Centro Piaggio, Universiteit Maastricht, Universidad Complutense de Madrid, Foundation for Research and Technology Hellas, University of Newcastle Upon Tyne, Dublin City University, BE WARRANT, BIOMECH INNOVATIONS, FLUIDINOVA, Tecnología Navarra de Nanoproductos SL, NOVAICOS, YODIWO), CELLINK has received funding for the project at 100 percent of the project´s total estimated costs: approximately €5,700,000. The GIOTTO project will be coordinated by Politecnico di Torino – Prof. Chiara Vitale-Brovarone. The project spans over 48 months and CELLINK´s share of the project corresponds €300,000. CELLINK's counter performance is entirely within the lines of the company's regular operations.

For further information, please contact: 

Erik Gatenholm, CEO                                         Gusten Danielsson, CFO

Phone: +46 73 267 00 00                                  Phone: +46 70 991 86 04

E-mail: eg@cellink.com                                    E-mail: gd@cellink.com

About CELLINK

CELLINK is the first bioink company in the world and the leading 3Dbioprinter provider that focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic treatments. Founded 2016 and active in more than 45 countries, CELLINK is changing the future of medicine as we know it. To read more about CELLINK, please visit: www.cellink.com CELLINK is listed at Nasdaq First North with the ticker CLNK. Erik Penser Bank AB, tel: +46 8 463 80 00, is the Company's Certified Adviser 

Senaste pressreleaserna
November 14, 2018RegulatoryKallelse till årsstämma i CELLINK AB